Related Experiment Video
Updated: Feb 22, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
34.2K
Pemafibrate: First Global Approval
1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|September 21, 2017
Summary
Pemafibrate, a selective peroxisome proliferator-activated receptor-alpha (SPPARM) agonist, effectively treats hyperlipidaemia by improving lipid profiles. This article details its development and first global approval for managing high cholesterol and triglyceride levels.
Area of Science:
- Pharmacology
- Metabolic Diseases
- Drug Development
Background:
- Hyperlipidaemia poses significant cardiovascular risks.
- Current treatments have limitations in efficacy and side effect profiles.
- Novel therapeutic agents targeting lipid metabolism are needed.
Purpose of the Study:
- To summarize the development milestones of pemafibrate.
- To highlight the first global approval of pemafibrate for hyperlipidaemia.
- To provide an overview of pemafibrate's mechanism of action.
Main Methods:
- Review of preclinical and clinical development data.
- Analysis of regulatory submission and approval processes.
- Pharmacological studies on peroxisome proliferator-activated receptor alpha (PPAR-α) modulation.
Main Results:
- Pemafibrate demonstrated significant efficacy in reducing plasma triglyceride levels.
- Pemafibrate showed a notable increase in high-density lipoprotein cholesterol levels.
- Successful completion of development leading to regulatory approval.
Conclusions:
- Pemafibrate is a novel and effective SPPARM for treating hyperlipidaemia.
- Its mechanism involves targeted regulation of lipid metabolism via PPAR-α.
- The drug's development represents a significant advancement in lipid-lowering therapies.
More Related Videos
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
289
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
289
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
30
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
30
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
591
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
591
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.4K